AstraZeneca Earnings Hit By Higher Costs
Wall Street Journal
AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.
Understanding current events through the lenses of the past and future.
Wall Street Journal
AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.